Quantbot Technologies LP bought a new stake in Avantor, Inc. (NYSE:AVTR – Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 270,653 shares of the company’s stock, valued at approximately $5,738,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Versant Capital Management Inc grew its holdings in shares of Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. grew its stake in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after buying an additional 1,391 shares during the last quarter. TFO Wealth Partners LLC increased its position in Avantor by 203,100.0% during the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock worth $46,000 after buying an additional 2,031 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH acquired a new position in Avantor during the first quarter worth approximately $93,000. Finally, ORG Partners LLC lifted its stake in Avantor by 5,773.0% in the second quarter. ORG Partners LLC now owns 5,873 shares of the company’s stock valued at $122,000 after buying an additional 5,773 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.
Avantor Trading Up 1.5 %
AVTR stock opened at $26.88 on Monday. Avantor, Inc. has a 52 week low of $16.63 and a 52 week high of $28.00. The company has a market cap of $18.27 billion, a price-to-earnings ratio of 68.92, a PEG ratio of 2.75 and a beta of 1.32. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. The business has a fifty day simple moving average of $24.42 and a 200-day simple moving average of $24.27.
Analysts Set New Price Targets
Several research analysts have weighed in on AVTR shares. Stifel Nicolaus lifted their target price on Avantor from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, July 29th. Citigroup cut shares of Avantor from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $30.00 to $23.00 in a research note on Wednesday, July 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of Avantor in a research report on Monday, July 29th. Wells Fargo & Company began coverage on Avantor in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Barclays boosted their price objective on shares of Avantor from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $27.40.
Read Our Latest Report on AVTR
Insiders Place Their Bets
In related news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.50% of the stock is owned by insiders.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Featured Stories
- Five stocks we like better than Avantor
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Analysts See 51% Upside in Coinbase, Is It Time to Buy the Hype?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Defensive Stock Alternatives to Bonds If Interest Rates Drop
- Airline Stocks – Top Airline Stocks to Buy Now
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.